—
C+
C+ The full Closelook — membership. Open the C+ overview

Kiniksa Pharmaceuticals Ltd (KNSA) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — Kiniksa Pharmaceuticals Ltd

KNSA in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Kiniksa Pharmaceuticals is a biopharmaceutical company that develops and sells therapies for autoinflammatory and cardiovascular conditions. Its approved medicine, Arcalyst, treats recurrent pericarditis, a chronic inflammation of the tissue around the heart, and cardiac sarcoidosis. The company is also testing KPL-387, a monoclonal antibody for the same pericarditis indication, in a combined Phase 2 and 3 trial, alongside KPL-116, an earlier antibody still in pre-clinical testing. Kiniksa operates across the United States, the United Kingdom and other markets, and is headquartered in London.
Where it sits in the stack
Kiniksa carries no seat in our index; it sits in the diary's healthcare sector, within the specialty and generic drug manufacturers group, outside the AI build-out stack the diary otherwise tracks.
Who it is priced against
The diary has not assigned Kiniksa to a peer group, so no comparison set is drawn from our coverage.
Why Closelook tracks it
Kiniksa holds no seat in our index and carries no Closelook score yet, and the diary has not quoted it in any edition.
What the diary watches
The diary watches how the Phase 2/3 trial of KPL-387 progresses, since a readout would extend Kiniksa's pericarditis treatment options beyond Arcalyst.

Kiniksa Pharmaceuticals Ltd (KNSA) trades on US exchanges.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for KNSA, from the same nightly bakes the boards use. Research diary readings, not advice.

Who it is priced against Drug Manufacturers - Specialty & Generic · US · 8 names with week and year-to-date

Peer group

Drug Manufacturers - Specialty & Generic · US

This name carries no Closelook score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against KNSA on the nightly bakes; the Peers tab ranks the cohort on the Closelook scores where it exists.

Dividends and capital return no distribution in twelve months · buybacks 8 m USD in FY2025

Dividends and capital return

What KNSA pays out and buys back — distributions read from the price series, money terms from the filings.

  • Distributions No cash distribution recorded in the price series over the last three years
  • Buybacks, FY2025 8 m USD 0.1% of today's market value
  • Share count +10.6% in FY2025 31 m USD of stock-based compensation in the year
  • Capital returned 8 m USD · 30% of free cash flow dividends and buybacks together, against the year’s free cash flow

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 55/100 · S&P 500 fund at 58, above its 50- and 200-day averagesEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-17
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 94th percentile of the window, +2.7% over 20 sessions. Factor regime → 2026-09-17
  • Sovereign pressure Index 0.00 · down 0.41 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-17

FAQ · from the current data · as of 2026-09-18

Quick answers

What is Kiniksa Pharmaceuticals Ltd (KNSA)?

Kiniksa Pharmaceuticals Ltd trades as KNSA on the US exchange (US) in the Closelook research universe, as of the registry build of 2026-09-18.

Is KNSA in a Closelook index?

Not currently — Kiniksa Pharmaceuticals Ltd is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-18.

Where does KNSA trade against its moving averages?

Uptrend stack intact: Trades +7.1% vs the 50-day and +46.1% vs the 200-day average, 4.4% below the 52-week high and +125.4% off the 52-week low. Computed from daily closes. As of 2026-09-17 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does Kiniksa Pharmaceuticals Ltd do?

Kiniksa Pharmaceuticals is a biopharmaceutical company that develops and sells therapies for autoinflammatory and cardiovascular conditions. Its approved medicine, Arcalyst, treats recurrent pericarditis, a chronic inflammation of the tissue around the heart, and cardiac sarcoidosis. The company is also testing KPL-387, a monoclonal antibody for the same pericarditis indication, in a combined Phase 2 and 3 trial, alongside KPL-116, an earlier antibody still in pre-clinical testing. The diary has not assigned Kiniksa to a peer group, so no comparison set is drawn from our coverage.

Where does Kiniksa Pharmaceuticals Ltd sit in the AI build-out?

Kiniksa carries no seat in our index; it sits in the diary's healthcare sector, within the specialty and generic drug manufacturers group, outside the AI build-out stack the diary otherwise tracks. Kiniksa holds no seat in our index and carries no Closelook score yet, and the diary has not quoted it in any edition.

Does Kiniksa Pharmaceuticals Ltd pay a dividend?

No cash distribution shows in Kiniksa Pharmaceuticals Ltd’s price series over the last three years. In fiscal 2025 the company bought back 8 m USD of its own shares, 30% of that year’s free cash flow. The share count rose 10.6% over the fiscal year. The "Dividends and capital return" block on this page carries the lines.

What does this page show?

A live price chart with SMA overlays and drawing tools for KNSA, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Related in the Closelook universe

then Drug Manufacturers - Specialty & Generic. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.